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Abstract
Coagulopathy is a physiological response to massive bleeding that frequently occurs after severe trauma and is an
independent predictive factor for mortality. Therefore, it is very important to grasp the coagulation status of patients
with severe trauma quickly and accurately in order to establish the therapeutic strategy. Judging from the description
in the European guidelines, the importance of viscoelastic devices in understanding the disease condition of patients
with traumatic coagulopathy has been widely recognized in Europe. In the USA, the ACS TQIP Massive Transfusion
in Trauma Guidelines proposed by the American College of Surgeons in 2013 presented the test results obtained
by the viscoelastic devices, TEG® 5000 and ROTEM®, as the standard for transfusion or injection of blood plasma,
cryoprecipitate, platelet concentrate, or anti-fibrinolytic agents in the treatment strategy for traumatic coagulopathy
and hemorrhagic shock. However, some studies have reported limitations of these viscoelastic devices. A review in the
Cochrane Library published in 2015 pointed out the presence of biases in the abovementioned reports in trauma
patients and the absence of a quality study in this field thus far. A quality study on the relationship between traumatic
coagulopathy and viscoelastic devices is needed.
Background
Two of the major causes of coagulopathy in trauma
patients are coagulopathy secondary to hemorrhagic
shock due to massive bleeding and coagulopathy due to
severe head injury [1]. The release of tissue factor from
the damaged brain tissue is postulated as the cause of
coagulopathy due to severe head injury. The fundamen-
tal treatment for shock due to bleeding is treatment to
achieve hemostasis, but fluid infusion and blood trans-
fusion for long periods of time under insufficient
hemostasis may lead to the derangement of hemostasis
and the impairment of hemostasis due to hypothermia
[2–4]. Therefore, it is important to achieve hemostasis
quickly without missing the timing in which the patient
is able to cope with physiological changes in the early
stage of massive bleeding such as tachycardia, wetness,
and coldness in the extremities, and anxiety, rather
than cope with hypotension that is a physiological
response to massive bleeding. It is also important to
perform blood transfusion quickly and appropriately as
well as obtain immediate hemostasis for the treatment
of hemorrhagic shock that accounts for 90% of incidents
of traumatic shock. Since coagulation abnormality which
is a physiological response to massive bleeding frequently
occurs after severe trauma and is an independent pre-
dictive factor for mortality, it is very important to grasp
the coagulation status of the patient quickly and accur-
ately in order to establish the therapeutic strategy [1, 5].
It has been recognized that trauma patients are more
likely to die from intraoperative metabolic failure than
from a failure to complete operative repairs. Damage
control surgery (DCS) is surgery that is designed to re-
store normal physiology prior to normal anatomy in crit-
ically ill patients. DCS is important for the treatment of
trauma because the development of coagulopathy due to
radical hemostasis is fatal [5, 6]. DCS is a therapeutic
concept in which hemostasis is achieved in as short a
time as possible, physiological function is normalized by
postoperative intensive care, and then injury repair is
completed by planned reoperation if necessary [7].
For this purpose, the status and degree of coagulopathy
must be determined quickly with objective indicators.
For example, it is possible that continuation of a surgical
operation in a patient with a defect in coagulability fails
to save the life of the patient because of uncontrollable
bleeding. To avoid such a situation, the criteria known
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as the trauma triad of death (deadly triad) consisting of
hypothermia, metabolic acidosis, and coagulopathy have
been proposed for the introduction of DCS [7]. In actual
clinical practice, body temperature and acid-base equilib-
rium can be quickly measured. However, measurement of
prothrombin time (PT) that is commonly used as the indi-
cator of coagulability requires more than 60 min before
the result is obtained [8]. In addition, it has been said that
these indicators reflect the early stage of the coagulation
process and that the amount of thrombin produced in this
period is only 4% of the total prothrombin [9]. Further-
more, the PT and activated partial thromboplastin time
(APTT) do not necessarily reflect the in vivo status of
coagulability such as the influence of platelets, because
the tests are carried out by adding a blood clotting acceler-
ant to plasma separated from whole blood. The activated
clotting time (ACT) that uses whole blood may not reflect
the in vivo status of coagulability either, because the test
also only reflects the early stage of coagulation similar to
PT and APTT [10]. We review the principles of measure-
ment by viscoelastic devices and guidelines for the treat-
ment of traumatic coagulopathy.
Principle of measurement by viscoelastic devices
TEG5000 system
The Thrombelastograph (TEG®) is a device that measures
the change in viscoelasticity of whole blood without separ-
ating out the plasma. The TEG was developed based on a
concept reported by Hartert in 1948 [11]. The TEG® was
reported as the most rapid available test for providing
reliable information on coagulopathy in patients with
multiple injuries [12]. Since the usefulness of the TEG® for
monitoring coagulability during liver transplantation sur-
gery was reported in 1985 [13], this instrument has been
widely used in clinical settings. In addition to the TEG®,
the rotational thromboelastometer (ROTEM®) has been
used as a common viscoelastic device. A new device has
been developed in Japan, and it has a completely different
principle of measurement from that of conventional
point-of-care (POC) devices to assess coagulation and
hemostatic function. This device is the Total Thrombus-
Formation Analysis System (T-TAS®) whose measurement
principle will be explained elsewhere in this article.
As for the principle of measurement by POC devices,
the TEG®5000 and ROTEM® delta optically measure
changes in mechanical impedance to a sensor pin gener-
ated by clotting-induced change in elasticity of whole
blood in a cuvette after the addition of a coagulation ac-
celerant [14, 15].
ROTEM system
In the ROTEM® system, the results are displayed in a
graph in which the horizontal axis is time (min) and the
vertical axis is clot amplitude (mm) which represents the
firmness of the clot (Fig. 1). Various parameters can be
measured with the ROTEM® system such as the duration
from the start of measurement to the beginning of clot-
ting time, duration from the start of clotting to the time
when the clot amplitude representing clot firmness
reaches 20 mm (clot formation time, CFT) and its angle
(α angle), the clot amplitude every 5 min after the begin-
ning of clotting (A 5–30) and its maximum (maximum
clot firmness, MCF), the lysis index at 30, 45, and
60 min after the beginning of clotting (LI 30, 45, and
60), and the maximum lysis index (ML) which can be
monitored in real time. The results in a normal healthy
person are shown in Fig. 2, and the results in representa-
tive patients with a clotting abnormality are shown in
Fig. 3. In clinical practice, we observe complicated find-
ings in quite a lot of patients with some types of coagu-
lation abnormalities. Case 1 was an 80-year-old woman
who complained of vertigo (Fig. 4). She was referred to
Fig. 1 An example of results obtained using the ROTEM system. In the ROTEM® system, the results are displayed in a graph in which the
horizontal axis is time (min) and the vertical axis is clot amplitude (mm) based on the firmness of the clot. Various parameters can be
measured in real time such as clotting time (CT), clot formation time (CFT), the amplitude at 5 min (A5), maximum clot firmness (MCF),
maximum lysis (ML), and lysis index at 30 min (LI30)
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our hospital because of suspicion of cerebral bleeding.
Her past medical history showed that she underwent
artificial blood vessel replacement surgery for thoracoab-
dominal aortic aneurysm 8 years previously, and she had
chronic hepatitis C, liver cirrhosis (Child-Pugh class B),
and chronic atrial fibrillation. On admission to our
emergency department (ED), her consciousness was alert
and her vital signs were nearly stable except for slight
hypertension. Her blood profiles showed significantly re-
duced platelet count (3.5 × 104/μL) and fibrinogen level
(72.6 mg/dL), prolonged PT-international normalized ra-
tio (INR) (1.47), prolonged aPTT (41.0 s), elevated D
dimer level (23.89 μg/mL), and significantly elevated
thrombin-antithrombin complex (TAT) level (31.6 ng/
mL).We considered that her reduced platelet count also
indicated platelet dysfunction. In these data, the parame-
ters of fibrinolysis implied not hyperfibrinolysis but clot
retraction because the ML in EXTEM and APTEM was
15% or more [16]. This patient was not diagnosed with
any acute cerebrovascular disease, and she was discharged
on the same day.
In the TEG®5000 system, tests are carried out by adding
premanufactured reagents to a citrated or heparinized
whole blood sample in a cuvette. Reagents for TEG®5000
are as follows: kaolin, which is the basic reagent for acti-
vating the intrinsic pathway; heparinase that excludes the
effect of heparin; tissue factor that activates the extrinsic
pathway; batroxobin that induces abnormal fibrin forma-
tion; activated factor XIII that promotes fibrin cross-
linkage; arachidonic acid (AA) and adenosine diphosphate
(ADP) that activate the respective receptor on platelets;
and a platelet aggregation inhibitor, abciximab [14]. The
TEG®5000 system allows us to conduct six different tests
by using different combinations of these reagents. Kaolin
TEG is the basic test in TEG® and measures the clotting
activity of the intrinsic pathway. Kaolin TEG + heparinase
which consists of kaolin and heparinase can detect the in-
fluence of heparin. Rapid TEG® that uses kaolin and tissue
factor enables the rapid measurement of clot-forming
capacity. TEG functional fibrinogen that uses tissue fac-
tor and abciximab assesses fibrin-polymerizing activity.
Measurement of platelet function is a characteristic
function of TEG®, so-called TEG® platelet mapping. The
combination of batroxobin, activated factor XIII and
AA or the combination of batroxobin, activated factor
XIII and ADP can assess the influence of acetylsalicylic
acid or a P2Y12 inhibitor, respectively.
Figure 5 shows the typical presentation of measure-
ment data obtained by TEG®.
The TEG® and ROTEM® systems are based on the
same basic principle of measurement. The results that
can be obtained from the two systems are summarized
in Table 1.
We introduced the ROTEM® delta in the emergency
room of our hospital in January 2013. Clotting time
measured in the EXTEM test was a significantly reliable
predictor of sepsis-induced disseminated intravascular
coagulation (DIC) among 13 sepsis patients [17].
Fig. 2 The results in ROTEM in a normal healthy person
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Interestingly, the clotting time measured in EXTEM was
strongly correlated with the DIC score of the Japanese
Association for Acute Medicine [17]. We assessed the
differences in results between traumatized and septic
DIC cases that were diagnosed by the same DIC scoring
system [18]. This study found that the plasma fibrinogen
level and clot firmness measured in the FIBTEM test
were significantly different between groups with the
same severity. Another paper reported a patient with
asymptomatic hyperfibrinolysis diagnosed by ROTEM
secondary to anaphylactic shock [19]. In fact, hyperfibri-
nolysis was significantly associated with elevated serum
lactate level (≥4.0 mmol/L) among patients with sys-
temic circulatory insufficiency [20].
T-TAS system
T-TAS® is a device that observes the time course of
thrombus formation in whole blood flowing in a simu-
lated blood vessel at a constant rate [21]. Since the
pressure curve reflects the rate of thrombus formation
and thrombus firmness, coagulability and platelet func-
tion can be assessed by reading the pressure curve.
There are two types of chips having a built-in simulated
blood vessel, called PL-chip and AR-chip [22].
The PL-chip which is specialized for the assessment
of platelet function consists of a simulated blood vessel
in which the inner surface is coated with collagen [23].
Thrombus formation is observed using whole blood
anticoagulated with hirudin, a thrombin inhibitor.
Fig. 3 ROTEM results in patients with various hematologic abnormalities. a The result of lower clot amplitude in EXTEM indicates platelet
deficiency or fibrinogen deficiency or both. The normal result in FIBTEM indicates platelet deficiency. b The results of lower clot amplitude in
EXTEM and decreased clot amplitude in FIBTEM indicate fibrinogen deficiency. c Reduced clot firmness after reaching the MCF indicates the
influence of fibrinolysis, and reduced clot firmness by more than 15% from the MCF in EXTEM and FIBTEM but no change in clot firmness
after MCF in APTEM indicates hyperfibrinolysis. d CT is prolonged in INTEM but does not change or is shorter in HPTEM, and the influence of
heparin should be considered
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Platelets bind to collagen on the inner surface of the
simulated blood vessel via von Willebrand factor
(VWF) to generate shear stress. Platelets activated by
shear stress aggregate and trigger thrombus formation
in cooperation with fibrinogen and VWF. Figure 6
shows the actual monitor during measurement with a
PL-chip. Figure 7 shows the actual monitor during
measurement with an AR-chip. The built-in software
for analyzing thrombus formation, T-TAS® Zia (Fig. 8),
allows us to observe thrombus formation in a simulated
vessel of the AR-chip in detail.
In other tests using POC devices and routine coagula-
tion tests in clinical laboratories such as PT and APTT, a
coagulation accelerant is directly added and mixed with
the whole blood or plasma sample. On the other hand,
in the T-TAS® system, collagen or tissue factor that had
been coated on the inner surface of a simulated blood
vessel activates platelets or the coagulation system in a
part of the whole blood sample and then triggers physio-
logical thrombus formation.
We discovered the change in coagulation function of a
patient before and after the patient received hyperbaric
oxygen therapy (HBOT) [24]. Figure 9 shows a graph of
HBOT significantly reduced the clot formation ability of
whole blood.
Viscoelastic devices in the guidelines for the
treatment of traumatic coagulopathy in the USA
and Europe
The importance of taking into consideration traumatic
coagulopathy in the treatment strategy of trauma patients
in Europe can be understood from the title of the Euro-
pean guidelines for the treatment of trauma patients. We
showed only part of monitoring with viscoelastic devices.
Please check other authors’ comments to help the under-
standing for full guideline. And a European guideline is
mentioning as which use is being just recommended,
but an American guideline is mentioned until an in-
depth numerical analysis. The title of the guidelines
published in 2007 [25] was “Management of bleeding
Fig. 4 Results using the ROTEM system in a coagulopathic patient with complicated medical conditions. This was a ROTEM result in an 80-year-old
woman who complained of vertigo. She had undergone artificial blood vessel replacement surgery for thoracoabdominal aortic aneurysm 8 years
previously, and she had chronic hepatitis C, liver cirrhosis (Child-Pugh class B), and chronic atrial fibrillation. The ROTEM test revealed prolonged CT,
prolonged CFT, low alpha angle, and low clot amplitude in every test in EXTEM and INTEM. Additionally, significantly reduced clot firmness in FIBTEM
indicated fibrinogen dysfunction. This patient was not diagnosed with any acute cerebrovascular disease, and she was discharged on the same day
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following major trauma: the European guidelines,”
whereas that published in 2013 [26] was “Management
of bleeding and coagulopathy following major trauma:
updated European guidelines”; the word “coagulopathy”
was added to the title of the more recent guidelines, in-
dicating the growing importance of taking into consider-
ation coagulopathy in the treatment strategy of trauma.
The guidelines published in 2013 mentioned that visco-
elastic devices were beneficial for establishing the treat-
ment strategy and assessing the status of coagulopathy
in patients with hemorrhagic shock (grade 1C). Judging
from the description in the European guidelines, the im-
portance of viscoelastic devices in understanding the
disease condition of patients with traumatic coagulopa-
thy has been widely recognized in Europe.
In the USA, the ACS TQIP Massive Transfusion in
Trauma Guidelines proposed by the American College
of Surgeons in 2013 presented the test results obtained
by the viscoelastic devices, TEG® 5000 and ROTEM®, as
the standard for transfusion or injection of blood plasma,
cryoprecipitate, platelet concentrate, or anti-fibrinolytic
agents in the treatment strategy for traumatic coagulopa-
thy and hemorrhagic shock [27]. This description indi-
cates that the clinical application of viscoelastic device is
more widespread in the USA than in Japan. The guidelines
proposed cutoff points using test values obtained by TEG®
that indicate the need for transfusion or infusion as fol-
lows: plasma replacement if the duration from the start of
measurement to the beginning of clotting (R-time) > 9 s;
administration of plasma or cryoprecipitate (fibrinogen
Fig. 5 Example of TEG findings. The typical presentation of measurement data obtained by TEG® is shown. The data are displayed in a graph in
which the horizontal axis is time (min) and the vertical axis is clot firmness, similar to the ROTEM® system. Parameters are the duration from the
start of the measurement to the beginning of clotting (R-time), duration from the beginning of clotting to the time when the amplitude of clot
firmness reaches 20 mm (K-time), clot firmness (MA) and the fibrinolytic index (LY30)
Table 1 Comparisons of various parameters between TEG® and ROTEM®
TEG ROTEM Interpretation of the finding
R (reaction time) CT (clotting time) Time to initiation of clot formation
A (amplitude) Viscoelasticity of the blood clot. Reflecting the function and counts of platelet
and fibrinogen about thrombogenicity of fibrin clot.
K (clot kinetics) CFT (clot formation time) Time from starting of blood clotting to the clot amplitude reaches at 20 mm.
Reflecting the speed of clot polymerization.
α α (alpha angle) Rate of increase of clot amplitude. Reflecting the speed of fibrin clot.
MA (maximum amplitude) MCF (maximum clot firmness) Maximum of amplitude. Reflecting the clot strength.
TMA (time to
maximum amplitude)
Time to maximum amplitude. Reflecting the clot formation time.
LY LI (lysis index) Rate of decrease of clot amplitude. Reflecting the degree of fibrinolytic activity.
CLT (clot lysis time) Time from maximum to minimum of clot amplitude. Reflecting the degree of fibrinolysis.
ML (maximum lysis) Maximum rate of decrease of clot amplitude to MCF.
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preparation) if the duration from the beginning of clotting
to the time when the amplitude of clot firmness reaches
20 mm (K-time) > 9 s; administration of cryoprecipitate
(or fibrinogen preparation) or plasma if α angle <60°; ad-
ministration of platelet concentrate if the maximum amp-
litude (MA) < 55 mm; and injection of anti-fibrinolytic
agents such as tranexamic acid if the fibrinolytic index
(LY30) is >7.5%. The cutoff points using rapid TEG® that
indicate the need for transfusion or infusion are as follows:
plasma replacement if ACT > 128 s; administration of
plasma or cryoprecipitate (fibrinogen preparation) prepa-
rations if K-time > 2.5 s; administration of cryoprecipitate
(or fibrinogen preparation) or plasma if α angle <60°; ad-
ministration of platelet concentrate if MA < 55 mm; and
administration of anti-fibrinolytic agents such as tranex-
amic acid if LY30 > 3%. On the other hand, cutoff points
using test values obtained using ROTEM® that indicate
the need for transfusion or infusion are as follows: plasma
replacement if clotting time >100 s with EXTEM and/or if
clotting time >230 s with INTEM; administration of
cryoprecipitate (fibrinogen preparation) and/or plasma if
MCF < 8 mm with FIBTEM; administration of platelet
concentrate if MCF < 45 mm with EXTEM and MCF >
10 mm with FIBTEM; and administration of fibrinolytic
agents such as tranexamic acid if ML > 15% with EXTEM.
Reports on the relationship between the use of
viscoelastic devices and the outcome of trauma
Treatment outcome has been considered as an index of
the usefulness of information obtained by viscoelastic
devices for acute-phase treatment of trauma. There have
been a number of reports on the relationship between
the test results obtained by viscoelastic devices and out-
come in trauma patients [28–31]. One study reported
that mortality was 100% in patients manifesting fulminant
hyperfibrinolysis with a mean injury severity score (ISS) of
Fig. 6 Display screen during measurement with a PL-chip in the T-TAS system. The left window shows the measurement conditions such as flow
rate of blood and temperature in the simulated vessel. The status of blood flowing can be observed in the upper right window. The lower right
window shows a graph presenting the time course of thrombus formation. Blood flowing in a simulated blood vessel taken by a microcamera
can be observed in real time in the upper right window. The lower right window shows a graph presenting the time course of thrombus formation
in which the horizontal axis is time and the vertical axis is the measured pressure. This graph allows us to observe the process of thrombus
formation visually. The left window shows the measured numerical data and measurement conditions. Measurement conditions are the flow
rate of blood flowing in the simulated vessel and the temperature in the vessel, and these flowing conditions can be set freely. Therefore,
this device allows us to simulate thrombus formation in various blood vessels in the body. Another chip, the AR-chip, has a built-in simulated
blood vessel in which the inner lumen is coated with collagen and tissue factor. After adding Ca++ in the simulated vessel, citrated whole
blood is activated by the collagen and tissue factor. Then, a very firm thrombus is formed by activated platelets and coagulation factors.
Therefore, the AR-chip enables us to assess the cooperative capacity of platelets and the coagulation system in thrombus formation
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Fig. 7 Display screen during measurement with an AR-chip in the T-TAS system. The configuration of the screen is similar to that shown in Fig. 6
Fig. 8 Display screen of T-TAS Zia®. T-TAS Zia® is the built-in software that can analyze thrombus conditions in detail (thrombus formation in the
PL-chip can also be analyzed with the software in the most recent model, T-TAS plus®)
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48 [32]. It was also reported that abnormalities of R and
MA values measured by TEG® were independent predict-
ive factors for poor outcome [33–36]. It has been demon-
strated that prolongation of CFT and a decrease in MCF
which indicate a decrease in platelet count measured by
ROTEM® were correlated more strongly with poor out-
come than with mortality calculated with the Trauma
and Injury Severity Score (TRISS) equation [32, 37]. It
has been reported that a decrease in fibrinogen level
which is detectable in the early stage of coagulopathy
was also correlated with poor outcome, suggesting the
use of fibrinogen level as the standard for administra-
tion of cryoprecipitate and fibrinogen preparations [30].
The study also reported improved survival with infu-
sion and transfusion based on the measurement of the
fibrinogen level.
Abnormal findings in platelet mapping analysis with
TEG® that represented reduced platelet function were
frequently observed among patients who died of head
injury [38]. It was also reported that the outcome was
better in patients in a hypercoagulable state than in pa-
tients in a hypocoagulable state [31].
Algorithms for trauma care using viscoelastic
devices
A specific algorithm for transfusion strategy in trauma
patients based on test results obtained with ROTEM®
was reported from Parkland Memorial Hospital in 2015,
indicating the current spread of viscoelastic devices in
clinical practice in the USA [39]. In this algorithm,
patients were treated as follows: If ML was prolonged
with EXTEM, the patient was judged to have hyperfibri-
nolysis and tranexamic acid was administered as anti-
fibrinolytic treatment. If the clotting time was prolonged
with EXTEM, the patient was judged to have reduced
coagulability, and a plasma preparation was adminis-
tered. If the amplitude was reduced with FIBTEM, the
patient was judged to have fibrinogen dysfunction and
cryoprecipitate or a fibrinogen preparation was adminis-
tered. If the amplitude was not reduced, the patient was
judged to have platelet dysfunction and platelet concen-
trate was transfused.
On the other hand, Yin et al. [40] reported a goal-
directed transfusion protocol based on the results of
TEG® in patients with abdominal trauma in Nanjing
Hospital, China, in 2014. If the R value that represents
the time to early clot formation was prolonged, fresh
frozen plasma was administered and its dose was de-
cided according to the degree of prolongation. If the α
angle which is the angle of slope at 20 mm in amplitude
and represents the rate of fibrin cross-linkage is de-
pressed, the patient was considered to have fibrinogen
dysfunction and cryoprecipitate was additionally admin-
istered after fresh frozen plasma infusion. If the α angle
was normal but MA which represents the strength of
the blood clot was reduced, the patient was considered
Fig. 9 T-TAS® measurement of thrombus formation in a patient who underwent HBOT. The blue line represents the result obtained before HBOT,
and the red line represents the result obtained after HBOT. After HBOT, the coagulation function decreased
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to have platelet dysfunction or a coagulopathy, and
platelet concentrate or recombinant factor VII was ad-
ministered. Several studies conducted in other countries
reported the use of viscoelastic devices in trauma care
and demonstrated their usefulness for the assessment of
traumatic coagulopathy [32, 35, 41–44].
These viscoelastic devices will become an important
tool for establishing the treatment strategy in trauma
care patients in Japan in the future.
However, some studies have reported limitations of
these viscoelastic devices. A review in the Cochrane Li-
brary published in 2015 pointed out the presence of
biases in the abovementioned reports in trauma patients
and the absence of a quality study in this field thus far
[45]. The review concluded that PT and INR are the
most reliable parameters for monitoring traumatic coag-
ulopathy although these parameters are not perfect.
Thus, it mentioned that POC tests should be done with
devices used in clinical laboratories because the way of
processing was not established for hardly interpretable
results obtained with POC devices. At present, the use-
fulness of viscoelastic devices has been demonstrated
only for control of intraoperative bleeding in cardiac sur-
gery, and there has not been favorable evidence for the
usefulness of POC devices for transplantation control
and improvement of outcomes in trauma patients with
other pathologies [46]. To make good use of POC de-
vices in establishing the treatment strategy for patients
with traumatic coagulopathy in the future, it is necessary
to compare the results obtained from POC devices with
the results of PT and INR obtained by laboratory de-
vices. In addition, it may be necessary to clarify and
solve the problems of measurement using POC devices
and to verify the usefulness of viscoelasticity as a supple-
mentary test item after understanding its characteristics
in clinical application.
Conclusions
Viscoelastic devices will become an important tool in es-
tablishing the treatment strategy in trauma care patients
in the future. However, some studies have reported limi-
tations of these viscoelastic devices. A quality study on
the relationship between traumatic coagulopathy and the
results obtained with viscoelastic devices is needed.
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